Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Amr I. Al Abbas"'
Autor:
Jae Pil Jung, Alessandro Paniccia, Mazen S. Zenati, Herbert J. Zeh, Kenneth K.W. Lee, Nathan Bahary, Melissa E. Hogg, Ana Gleisner, Amr I. Al Abbas, David L. Bartlett, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 27:2961-2971
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Brian A. Boone, Joal D. Beane, Mazen S. Zenati, Herbert J. Zeh, A. James Moser, Melissa E. Hogg, David L. Bartlett, Amr I. Al Abbas, Amer H. Zureikat
Publikováno v:
Ann Surg
OBJECTIVES: This study aims to present the outcomes of our decade-long experience of robotic pancreatoduodenectomy and provide insights into successful program implementation. BACKGROUND: Despite significant improvement inmortality over the past 30 y
Autor:
Ahmad Hamad, Melissa E. Hogg, Caroline J. Rieser, Amr I. Al Abbas, Amer H. Zureikat, Nathan Bahary, Mazen S. Zenati, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 25(12)
Serum carbohydrate antigen 19-9 (CA19-9) correlates with response to therapy and overall survival (OS) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aimed to define the chronologic relationship between CA19-9 elevation and rad